Memo Therapeutics
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Memo Therapeutics has raised €96M across 4 funding rounds from 15 investors, most recently a Series C round in May 2024. Based in Zurich, Switzerland; founded 2012; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€96M
€95,537,434
Funding rounds
4
Investors
15
distinct backers
Active since
2020-11
latest 2024-05
Funding by year
EUR raised per yearMemo Therapeutics — funding by year — interactive chart.
Data table
| Memo Therapeutics — funding by year | |
|---|---|
| 2020 | €14M |
| 2022 | €35M |
| 2023 | €26M |
| 2024 | €20M |
Signals
High confidenceRaise-next likelihood17
base rate 50% for Series C
- ▼ Past typical raise window
- ▼ Down/flat last round
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 4 rounds raised
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
4 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-05-07 | Series C | €20M | Kurma Partners,Ysios Capital | View deal → |
| 2023-11-02 | Series C | €26M | Adjuvant Capital,Fresenius Medical Care Ventures,GF Group Holding,Pureos Bioventures,Redalpine,Schroders Capital+3 more | View deal → |
| 2022-02-16 | Series B | €35M | Adjuvant Capital,Fresenius Medical Care Ventures,GF Group Holding,Swisscanto Invest,Verve Ventures,Vesalius Biocapital Partners+1 more | View deal → |
| 2020-11-06 | Series A | €14M | Redalpine | View deal → |
Investors
15Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData